<DOC>
	<DOC>NCT02955602</DOC>
	<brief_summary>An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)</brief_summary>
	<brief_title>MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) (8 Week, Dose Ranging, Open Label, Randomized Phase 2 With an Extension)</brief_title>
	<detailed_description>Primary: To evaluate the safety and efficacy of MBX-8025 5 mg, 10 mg, and 25 mg over 8 weeks of treatment Secondary: To evaluate the safety and efficacy of MBX-8025 5 mg, 10 mg, and 25 mg over 26 weeks of treatment To evaluate the pharmacokinetics (PK) of MBX-8025 Exploratory: To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and renal function</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1. Must have given written informed consent (signed and dated) and any authorizations required by local law 2. 18 to 75 years old (inclusive) 3. Male or female with a diagnosis of PBC, by at least two of the following criteria: History of AP above ULN for at least six months Positive AMA titers (&gt;1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBCspecific antinuclear antibodies Documented liver biopsy result consistent with PBC 4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to UDCA 5. AP ≥ 1.67 × ULN 6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose 1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment) 2. AST or ALT &gt; 3 × ULN 3. Total bilirubin &gt; 2.0 mg/dL 4. Autoimmune hepatitis 5. Primary sclerosing cholangitis 6. Known history of alpha1Antitrypsin deficiency 7. Known history of chronic viral hepatitis or HIV infection 8. Creatine kinase above ULN 9. Serum creatinine above ULN 10. For females, pregnancy or breastfeeding 11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening 12. Current use of fibrates or simvastatin 13. Current use of obeticholic acid 14. Current use of an experimental or unapproved treatment for PBC 15. Current use of experimental or unapproved immunosuppressant 16. Adverse event leading to MBX8025 discontinuation from CymaBay's phase 2 PBC study (CB802521528) 17. Hepatic decompensation (e.g., known history of esophageal variceal bleed, ascites, hepatic encephalopathy) 18. Acute pancreatitis or known history of chronic pancreatitis 19. Any other condition(s) that would compromise the safety of the subject (e.g., uncontrolled diabetes, uncontrolled hypertension, severe osteoporosis) or compromise the quality of the clinical study (e.g., subjects with drug or alcohol abuse), as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PBC</keyword>
	<keyword>Primary Biliary Cholangitis (PBC)</keyword>
</DOC>